In summary, our study demonstrated that most HER2-positive BC patients, particularly those with HR-negative status, benefit significantly from anti-HER2 neoadjuvant therapy (HLX02 and/or pertuzumab in combination with chemotherapy). The gene discussed is ERBB2; the disease is breast cancer.